Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess - sprookjes - yvandenbroek - TriplyDB

Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess

Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess

http://www.wikidata.org/entity/Q24539134

about

Dimerization and enzymatic activity of fungal 17beta-hydroxysteroid dehydrogenase from the short-chain dehydrogenase/reductase superfamily.Apparent mineralocorticoid excess syndrome: an overview In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research.Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.Hormonal hypertension in children: 11beta-hydroxylase deficiency and apparent mineralocorticoid excess.The genetics of essential hypertension.Genotype-phenotype correlations of mutations and polymorphisms in HSD11B2, the gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase.Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases.Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice.Heritable forms of hypertension.11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders.Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond.Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure.Glucocorticoid synthesis-related genes: HSD11B1 and HSD11B2 in hypertensive disorders in pregnancy.Grapefruit juice inhibits 11beta-hydroxysteroid dehydrogenase in vivo, in man.The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement.11beta-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension.Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene.Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.

P2860

Q25256625-BAD31259-BB34-4A8A-B4D6-73137F61383C Q28239329-6022F842-79BB-4A9B-818F-24C723A6CC24 Q30390640-3FAF613F-97C6-40D9-A360-C2AD0C01EF30 Q30883430-169FF2DB-7B9F-4DD6-A35B-2BF7F22D2F8C Q32066578-91876C7A-8CCC-417E-B203-7519FB9F83BF Q34128709-A14EB817-C02F-432F-8D3B-14D5A08D30E6 Q34135261-6D2AC925-C3DC-4938-99F7-A512CEDCB8B1 Q34150386-6EC1DE85-DB82-4EFC-8F13-8253E7CDB387 Q36079020-FF706D14-9307-4EEE-B63B-7B082A643B5A Q36232568-A1956810-149E-4EEE-B006-B4FF348ABEC3 Q36890057-D3C4D573-A1B6-430E-9775-5B2CCD5A34A0 Q37655884-18F0D5A6-5521-4DBD-B217-6F0A8DB7A8FC Q38221451-E979D490-B0B3-41FF-825F-B499C503AAA6 Q38790409-317267B4-8A46-4E06-8FF0-7FA722C96438 Q40129518-DAD8D3CE-FD5C-47F4-A0D6-17C3A0E5FE71 Q44010043-21A01CB9-31DB-4729-9915-19F12F49A063 Q44478614-FFDC2395-A730-479B-91EE-F3389471769F Q44655362-D619229D-67C5-45F7-BB47-6EDF65178461 Q45200507-A83AD849-4E0F-4CBB-9A33-FEECA78D46CD Q46147309-C87AD669-5E50-4AC3-80D2-826833175E6B Q47304913-72B97C41-5D4E-4FC3-AEDD-2D07B02E7725

P2860

Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess

http://www.wikidata.org/entity/Q24539134

description

1998 nî lūn-bûn

@nan

1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@ast

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@en

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@nl

type

label

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@ast

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@en

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@nl

prefLabel

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@ast

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@en

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@nl

P1433

Q24539134-33DD7F1E-7D71-4A80-A633-CB65BB3A1A72

P1476

Q24539134-BF223DB1-C847-4F3B-B8A2-2C790FF22CEF

P2093

Q24539134-0897488B-6F1C-4EBB-B96F-B0F73D939BD3

Q24539134-1D843925-FE51-475E-9595-3431D9F09EDF

Q24539134-3C37FAC9-7B87-4C9E-9024-6D3FE61F2815

Q24539134-4DB50677-FBE4-47F8-952C-FD309DD7A508

Q24539134-553238F1-BE37-46C1-A46B-753D6C4F3A4D

Q24539134-8E7367F2-CC74-48A5-A105-7DDD181CA126

Q24539134-AFCF687B-A134-4CC2-BDA7-D81A765897BB

Q24539134-BBE73E92-7E68-4E68-BF78-01DBC05DEF61

Q24539134-C268DC17-8E0F-48E7-81F4-B886A5D89E6E

P2860

Q24539134-0612D910-0AE6-4949-9C69-ED43BC585614

Q24539134-0AED06B5-F6D8-4759-8888-AACD783C86F0

Q24539134-1D414F58-70DF-4ACA-8E74-978456EDAADE

Q24539134-1EBBF6AC-6EBC-4D6C-BB05-EBD808DDBA86

Q24539134-22A09734-09D8-41FF-BA2B-744344A5C2F4

Q24539134-25A2075E-017F-4C02-9319-855AE7F7D6D9

Q24539134-26A04E12-9101-4535-A0C0-4EA9D661A7ED

Q24539134-297E0E40-BC12-409F-AE59-A665D0B8F623

Q24539134-47884FE6-74EE-42D3-819D-CCE6566816BE

Q24539134-5C943ABF-2AB5-4DBE-B164-79F2203CF2AF

P304

Q24539134-362FDE2D-3AF9-4AFC-B3F6-FD48E70FCB62

P31

Q24539134-E5430E41-C19D-41DE-B198-B7756ACB9C68

P356

Q24539134-2ADE75F7-7F5B-43E2-938E-66A6019772E8

P407

Q24539134-4FCF583C-F34B-414A-986A-4491BABCB159

P433

Q24539134-0B4FFCD5-4190-43C5-B9A5-51C624C8F6C8

P478

Q24539134-D655BC0D-95E5-4952-A45E-EE8FF2806372

P577

Q24539134-37C32FC7-917D-434D-A2C9-B9FCFAEFD542

P5875

Q24539134-00220CB9-8CE3-4E84-B19E-132343E69274

P698

Q24539134-DA21ADE1-51A1-4730-84C4-2B327B3737D1

P921

Q24539134-34A1B715-7980-456F-9E28-8D01D293629C

Q24539134-B2C77421-0FDD-4EC1-861C-6BF5922DED50

P932

Q24539134-7871450A-D45F-4CE7-B6EA-DD3EA9F7D758

P356

P1433

American Journal of Human Genetics

P1476

Molecular basis for hypertensi ...... arent mineralocorticoid excess

@en

P2093

Krozowski ZS

http://www.w3.org/2001/XMLSchema#string

Li A

http://www.w3.org/2001/XMLSchema#string

Li KX

http://www.w3.org/2001/XMLSchema#string

Mantero F

http://www.w3.org/2001/XMLSchema#string

Pala A

http://www.w3.org/2001/XMLSchema#string

Palermo M

http://www.w3.org/2001/XMLSchema#string

Shackleton CH

http://www.w3.org/2001/XMLSchema#string

Stewart PM

http://www.w3.org/2001/XMLSchema#string

Tedde R

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor

Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme

Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene

Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated

Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age

Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess

A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess

The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization

Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase

11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess

P304

370-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/301955

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

1998-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13600766

http://www.w3.org/2001/XMLSchema#string

P698

9683587

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

mineralocorticoid

P932

1377297

http://www.w3.org/2001/XMLSchema#string